Navigation Links
Kendle Named a 'Best Place to Work' in Greater Cincinnati
Date:11/6/2008

CINCINNATI, Nov. 6 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) today announced it has been named a "Best Place to Work" in Greater Cincinnati by the Cincinnati Business Courier in the "Grand" company category among first-time participants. Winners were announced today at the Greater Cincinnati Best Places to Work luncheon.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

"Kendle is proud to be recognized as an employer of choice," said Candace Kendle, PharmD, Chairman and CEO. "Our tremendous growth and success in recent years is a result of their unwavering passion in working to bring new medicines to market to save and enhance the lives of people across the world. We value the contributions of our associates and work hard to create a stimulating and rewarding culture that engages them through ongoing learning and career development opportunities to advance their skills and accelerate their careers."

Greater Cincinnati's Best Places to Work were chosen based on scores from employee surveys which measured employee engagement, trust in management and coworkers, belief in career path, commitment to professional development, satisfaction with compensation and benefits as well as overall employee workplace fulfillment. Results were analyzed by an independent research company to determine winners in four categories; small-, medium-, large- and grand-sized businesses.

More than 100 companies participated in the Greater Cincinnati's Best Places to Work 2008 survey. The awards program is open to any company based in the 15-county Greater Cincinnati region with 10 or more employees and companies not based here but which have at least 75 local employees. The program has been conducted annually by the Business Courier since 2003.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has been recognized as "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
2. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
3. Kendle to Present at the UBS Global Life Sciences Conference
4. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
5. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
6. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
7. Kendle Appoints Patricia Williams Vice President, Commercial Operations
8. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
9. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Kendle Leaders Adopt 10b5-1 Trading Plans
11. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):